Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BVS
Strong BuyFull HouseAPPROVEBioventus Inc. · Healthcare · United States · $945M · Avg Vol: $10M/d
Bioventus passes all eligibility thresholds (Quality 74, Value 56, Momentum 76) and shows a constructive EPS revision trend. No adverse insider activity or governance flags noted.
COMPANY DESCRIPTION
Bioventus Inc. is a global medical technology company focused on developing and commercializing orthobiologic solutions for musculoskeletal conditions, including bone healing, pain management, and surgical applications. Its competitive edge stems from a diversified portfolio of clinically-backed, often patented products that address significant unmet needs in orthopedics. The company serves a specialized market through strong relationships with healthcare professionals.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 512.1M | 512.3M | 573.3M | 568.1M | 3.5% | 581.8M | 604.8M | 645.5M | 6.6% |
| EPS | -0.15 | -2.59 | -2.49 | -0.52 | 0.34 | — | 0.78 | 0.39 | 0.46 | 16.3% |
| Shares | — | 62.1M | 63.3M | 65.8M | 67.1M | +8.1% | 68.3M | — | — | — |
| Debt | — | 418.1M | 394.8M | 335.6M | 294.0M | -11.1% | 263.7M | — | — | — |
| Equity | — | 325.2M | 173.6M | 147.9M | 184.1M | -17.3% | — | — | — | — |
| Op CF | — | -13.5M | 15.3M | 38.8M | 74.7M | 120.6% | 96.9M | — | — | — |
| Inv CF | — | -116.4M | 15.8M | 23.0M | -3.2M | — | — | — | — | — |
| Fin CF | — | 62.1M | -26.7M | -54.6M | -62.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BVS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BVS | Bioventus Inc.(you) | $945M | 96 | Strong Buy |
| CNMD | CONMED Corporation | $1.5B | 87 | Strong Buy |
| DCTH | Delcath Systems, Inc. | $567M | 87 | Strong Buy |
| TCMD | Tactile Systems Technology, Inc. | $525M | 87 | Strong Buy |
| INSP | Inspire Medical Systems, Inc. | $1.8B | 83 | Strong Buy |
| IART | Integra LifeSciences Holdings Corporation | $1.3B | 75 | Buy |
| VREX | Varex Imaging Corporation | $780M | 71 | Buy |
| VMD | Viemed Healthcare, Inc. | $336M | 87 | Strong Buy |
| IRMD | IRADIMED CORPORATION | $1.1B | 65 | Buy |
| UFPT | UFP Technologies, Inc. | $2.3B | 80 | Strong Buy |
Peer medians: ROE -30.8% · P/E 27.1x · Gross margin 58.1%